Among 11 JMML children, two had an abnormal karyotype, and nine had a normal karyotype at onset. In one patient with trisomy 8 and four patients with a normal karyotype, a new clone with an aberrant karyotype emerged 1-14 months after 6-mercaptopurine (6-MP) therapy as shown by G-banding analyses. Fluorescence in situ hybridization disclosed that an abnormal clone existed in approximately 3-6% of bone marrow cells at onset or before 6-MP therapy in all the four cases examined, and increased to approximately 12-90% during the treatment. In culture with granulocyte-macrophage colonystimulating factor, cytogenetically abnormal clones that proliferated during 6-MP therapy possessed significantly less sensitivity to the antimetabolite, compared with cells that decreased in numbers after the therapy. A PTPN11 mutation was detected in all of granulocyte-macrophage colonies irrespective of karyotypic aberration in one patient, whereas approximately 80% of erythroid colonies and 20% of mixed colonies possessed neither a PTPN11 mutation nor chromosomal abnormalities. The appearance of chromosomal aberrations shown by G-banding during 6-MP therapy in some JMML cases may result, in part, from the growth of a 6-MP-refractory clone that already exists at onset. It is possible that treatment with 6-MP promotes progression of the disease.
Introduction
Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disorder of early childhood. Diagnostic criteria for the disorder were proposed by the International Juvenile Myelomonocytic Leukemia Working Group in 1998, 1 and have been widely accepted. Recent studies have disclosed that Ras dysregulation as well as resistance to apoptosis account for the myeloproliferation in JMML. 2, 3 Activating mutations of the N-ras and K-ras genes are found in some patients with JMML, whereas other patients show loss of heterozygosity of the tumor suppressor gene NF1. 4, 5 Recently, somatic mutations within PTPN11, which encodes the protein tyrosine phosphatase Shp-2, have also been reported to occur frequently in JMML. 2 In the report of the European Working Group on myelodysplastic syndrome (MDS) in childhood, 6 the probability of survival at 10 years was 6% for patients who did not receive bone marrow (BM) transplantation. On the basis of statistical analyses in this non-BM transplantation group, age, platelet count, and hemoglobin F (HbF) at the time of diagnosis were the most important prognostic factors for the length of survival. Among the criteria considered by the International Prognostic Scoring System (IPSS) score for MDS, a platelet count 440 Â 10 9 /l was significantly associated with a superior survival in JMML, but other IPSS factors including cytogenetics were not. 7 Allogeneic hematopoietic stem cell transplantation (HSCT) is presently the only curative treatment for this disorder. Chemotherapy approach does not consistently improve the outcome for children with JMML, 8, 9 but treatment with 6-mercaptopurine (6-MP) is sometimes used to ameliorate leukocytosis as a pretransplant therapy. 10 Niemeyer et al. 6 reported that according to standard cytogenetic analyses, two-thirds of patients with JMML were of normal karyotype in BM cells at diagnosis, whereas the remaining patients had chromosomal aberrations including monosomy 7. We have had some JMML patients who initially possessed a normal karyotype but acquired chromosomal abnormalities during treatment with 6-MP. One possible explanation for karyotypic evolution is that G-banding analyses missed a meager population with an abnormal karyotype that already existed at onset and that this population increased during 6-MP therapy because of resistance to the antimetabolite. The aim of the present study is to test this possibility.
Materials and methods

Isolation of BM mononuclear cells
Informed consent was obtained from the guardians of the patients following institutional guidelines. Bone marrow mononuclear cells (MNCs) were separated by density centrifugation over Ficoll-Paque (Pharmacia, Piscataway, NJ), washed twice, and suspended in alpha-medium. The samples were frozen with liquid nitrogen until the experiment.
Detection of PTPN11 mutations and N-ras mutations
Exons 3, 8 and 11 of PTPN11, and exon 1 (codons 12 and 13) and exon 2 (codon 61) of N-ras were amplified by PCR, using primer pairs described previously. 11, 12 A total of 100 ng of genomic DNA was amplified in a 20 ml reaction buffer containing 2.5 mM of each primer, 0.2 mM of deoxynucleotide triphosphate, 1.5 mM of MgCl 2 and 1.0 U of AmpliTaq Gold DNA Polymerase (Perkin-Elmer Corp., Foster City, CA). For PCR of PTPN11, the samples were denatured at 951C for 10 min, then subjected to 30 cycles at 951C for 1 min, at 581C for 1 min, and at 721C for 1 min with a final 10 min of extension at 721C. In the case of N-ras, the samples were denatured at 951C for 10 min, then subjected to 30 cycles at 951C for 30 s, at 551C for 30 s, and at 721C for 1 min with a final 10 min of extension at 721C. The PCR products were subjected to direct sequencing from both directions on an automatic DNA sequencer (ABI Prism 3100 Genetic Analyzer, Applied Biosystems, Foster City, CA). A homology search of the GenBank database was performed, using the cDNA sequence of the human PTPN11 gene or N-ras gene (GenBank accession nos. NM002834, X00642, and X00643 as the query).
FISH analysis
FISH analysis was performed according to a modification of a procedure described previously. 13 We obtained probes specific for the centromere of chromosome 8 (CEP 8), of chromosome 11 (CEP 11), of chromosome X (CEP X), or of chromosome Y (CEP Y), and for the MLL gene (LSI MLL) from Vysis (Downers Grove, IL). We also used a probe that hybridized to the region of the elastin gene (7q11.23) and to a specific sequence (D7S427) at 7q36 (Elastin-Williams syndrome chromosome region probe with D7S427 chromosome 7 control probe; Oncor Inc., Gaithersburg, MD).
We scored 500 nuclei from each BM specimen for the number of hybridization signals. The cutoff limits were defined as the mean þ 2 s.d. obtained from BM smears of four normal controls that were kept in liquid nitrogen, as FISH analyses were performed on frozen marrow cells of JMML patients.
Suspension cultures
Fifty thousand BM MNCs were cultured in each well of 24-well culture plates (#3047; Becton Dickinson, Mountain View, CA) containing 2 ml of alpha-medium (Flow Laboratories, Rockville, MD) supplemented with 10 ng/ml of granulocyte-macrophage colony-stimulating factor (GM-CSF) and 10% fetal bovine serum.
14,15 6-MP (Sigma Chemical, St Louis, MO) was dissolved in 1 N sodium hydroxide, and then diluted with alpha-medium. The plates were incubated at 371C in a humidified atmosphere flushed with 5% CO 2 in air. After 7 days, the number of viable cells was determined by a trypan-blue exclusion test using a hemocytometer.
Clonal cell culture
Clonal cell cultures were carried out in 35-mm Lux suspension culture dishes (#171099; Nunc, Naperville, IL), as described previously. 14, 15 One thousand CD34 þ BM cells of Case 5 were plated in a dish containing methylcellulose medium supplemented with GM-CSF, stem cell factor, interleukin-3, and erythropoietin (Methocult GF H4434, Stemcell Technlogies Inc., Vancouver, Canada). Dishes were incubated at 371C in a humidified atmosphere flushed with 5% CO 2 . On day 12, GM colonies, erythroid colonies, and mixed colonies were individually lifted with an Eppendorf micropipet, and prepared as single cell suspensions. Then, both FISH and sequence analyses were performed on each colony-constituent cell.
Statistical analysis
In experiments comparing sensitivity to 6-MP between cells with an abnormal karyotype and cells with a normal karyotype, values are expressed as means7s.d. We used the one-way analysis of variance, followed by post hoc contrasts with the Bonferroni limitation as a statistical analysis. To determine the significance of differences between two independent groups, we used the unpaired t-test.
Results
Chromosomal change after chemotherapy in JMML
A total of 11 children were diagnosed as having JMML between 1980 and 2003 in Shinshu University Hospital and Niigata Cancer Center Hospital. All the patients met the criteria proposed by the International JMML Working Group, 1 but did not have clinical features of neurofibromatosis type I. Spontaneous growth and/or hypersensitivity to GM-CSF of BM GM progenitors were demonstrated in all the patients by semisolid colony assay.
14 As presented in Table 1 , G-banding analyses at diagnosis revealed that two patients had an abnormal karyotype (47,XY, þ 8 and 45,XY, À7), and the remaining nine patients had a normal karyotype. Six of 10 patients examined had PTPN11 mutations, whereas one patient had N-ras mutation.
Various kinds of chemotherapy including treatment with 6-MP were performed to ameliorate leukocytosis in all patients, seven of whom subsequently received HSCT. After treatment for JMML, seven patients showed significant chromosomal change, as determined by G-banding analyses. Karyotypic alteration was observed 1-14 months after the administration of 6-MP alone or in addition to 13-cis retinoic acid (RA) in five patients (Cases 1-5). When new clones with an aberrant karyotype appeared, the patients had leukocyte counts ranging from approximately 2 Â 10 9 to 20 Â 10 9 /l. In addition, neither substantial elevation in the percentage of blasts in BM nor significant exacerbation of hepatosplenomegaly was found. On the other hand, chromosomal changes were observed 8 months after HSCT in Case 6, and 3 months after intensive chemotherapy in Case 7. In Case 6, the initial clone with monosomy 7 did not disappear while the patient was on therapy, but acquired additional aberrations after HSCT.
FISH analyses in JMML patients with chromosomal evolution after treatment with 6-MP Serial G-banding analysis in Case 5 revealed that 60% of BM cells had trisomy 8 on admission, but this proportion markedly decreased to approximately 15% 2 months after 6-MP treatment (Table 2) . On the other hand, a clone with ÀY was not found in BM at onset, but approximately 80% of BM cells were missing the Y chromosome following 6-MP treatment. From the karyotypic change, we speculated that a population with ÀY already existed at onset, and was resistant to 6-MP. As a result, it appeared during treatment with the antimetabolite in JMML patients with chromosomal evolution during 6-MP therapy. To test this possibility, we conducted serial FISH analyses on four patients (Cases 1, 3-5), whose bone marrow cells before and after 6-MP therapy were kept in liquid nitrogen, and then the susceptibility of the cells with an abnormal karyotype appearing during 6-MP therapy to the antimetabolite was examined.
Case 1. We used a probe that hybridized to the region of the elastin gene at 7q11.23 and a probe for a specific sequence (D7S427) at 7q36. Cells with two signals for the elastin gene and two signals for D7S427 per nucleus were considered normal pattern, whereas cells with two signals for the elastin gene and one signal for D7S427 were considered to have 46,XX,add (7) Case 3. We used a probe for the centromere of chromosome 11 and a probe specific for MLL at 11q23 for FISH analyses. Cells with two signals for chromosome 11 and two signals for MLL were considered normal pattern, whereas those with two copies of chromosome 11 and three copies of MLL were considered to have 46,XY,der(20) t(11;20)(q13;q13). Whereas 474 (94.8%) of 500 BM cells of the patient, before the administration of 6-MP, had two signals for chromosome 11 and two signals for MLL per nucleus, the remaining 26 cells (5.2%) had two signals for chromosome 11 and three signals for MLL. In all, four normal controls, 500 cells had normal copy numbers of chromosome 11 and MLL. At 1 month after 6-MP therapy, the frequency of the abnormal clone increased to 11.8% in the FISH analysis, and to 15% in the G-banding analysis. We could not perform FISH at diagnosis because of a lack of frozen samples. 
FISH and sequence analyses of each colony-constituent cells in Case 5
Of the six patients who acquired chromosomal abnormalities at onset and/or after non-intensive chemotherapy, five had PTPN11 mutations. To examine whether 6-MP-refractoriness was achieved by either karyotypic changes or PTPN11 mutations, GM colonies, erythroid colonies, and mixed colonies grown from CD34 þ BM cells at onset and after 6-MP therapy, under stimulation with the combination of growth factors, were individually picked up in Case 5. Then, both FISH and sequence analyses were performed on each colony-constituent cells. As Table 2 Cytogenetic analyses in four JMML patients with chromosomal change during 6-MP therapy In FISH analyses, 500 JMML bone marrow cells that were kept in liquid nitrogen were scored. We used four normal bone marrow samples handled in the same manner as controls. The values in parentheses indicate the cutoff limits in FISH analyses. * * The serial FISH analysis revealed that karyotypically abnormal clones were infrequent before 6-MP therapy, but apparently increased in number to account for approximately 12-90% of BM cells after the treatment in four of the cases described above. In our liquid cultures for Cases 3-5, cytogenetically abnormal clones that proliferated during treatment with 6-MP possessed significantly less sensitivity to the antimetabolite, when compared with cells that decreased in numbers after the therapy. Therefore, the appearance of the cells with chromosomal aberrations shown by G-banding during treatment with 6-MP may result from the growth of a 6-MP-refractory clone that already existed prior to the administration of the antimetabolite.
Neither moderate nor intensive chemotherapy has been demonstrated to consistently improve the outcome for children with JMML. 8, 9 Allogeneic HSCT is presently the only curative treatment for this disorder; however, a high rate of relapse after HSCT has been reported. 10, 16 In Cases 4 and 5, a 6-MP-resistant clone with a chromosomal aberration re-appeared even after HSCT. In some JMML patients, leukemic cells may possess resistance to other types of anticancer drugs as well as to 6-MP.
According to the report of Niemeyer et al., 6 two-third of patients with JMML are of normal karyotype in BM cells at the time of diagnosis, while the remaining patients have chromosomal aberration. They proposed age, platelet count, and Hb F, but not karyotype, at diagnosis as factors for predicting the length of survival. On the other hand, in a nationwide survey in Japan, abnormal karyotype was the only significant risk factor for a lower overall survival of JMML patients who received allogeneic HSCT. 10 In the present study, the FISH method disclosed a minor abnormal clone that was missed by the conventional G-banding analyses at onset in some JMML patients. Accordingly, it may be necessary to re-evaluate chromosomal abnormality as a prognostic parameter.
Of the six patients who acquired chromosomal abnormalities at onset and/or after non-intensive chemotherapy, five had PTPN11 mutations. In Case 5, a PTPN11 mutation was detected in all 50 GM colonies (13 GM colonies with trisomy 8, 7 GM colonies with deletion of Y, and 30 GM colonies with normal copy numbers of the two chromosomes). Thus, 6-MP-refractoriness in JMML appears to be achieved by karyotypic change, but not PTPN11 mutation.
In some patients with JMML, clones with cytogenetic changes seem to be selected by 6-MP therapy. Accordingly, it is possible that treatment with 6-MP promotes progression of the disease. The karyotypic alteration, however, could also be caused by other drugs in the disorder. One thousand CD34 + BM cells of Case 5 were cultured in a dish containing GM-CSF, stem cell factor, interleukin 3 and erythropoietin. On day 12, 50 GM colonies, 16 erythroid colonies, and 10 mixed colonies were individually picked up. Then, both FISH and sequence analyses were performed on each colony-constituent cells. The values in parentheses are the numbers of colonies with a PTPN11 mutation (226G4A).
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